Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Journal für Gynäkologische Endokrinologie/Schweiz
Erschienen in:

03.03.2021 | Menopause

Schilddrüsenerkrankungen in der Peri- und Postmenopause

verfasst von: Dr. med. Antonia Mondorf, Gesine Meyer, Jörg Bojunga

Erschienen in: Journal für Gynäkologische Endokrinologie/Schweiz | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Von der mit fortschreitendem Lebensalter zunehmenden Prävalenz von Schilddrüsenerkrankungen sind Frauen deutlich häufiger betroffen als Männer. Symptome einer Schilddrüsenerkrankung sind oft unspezifisch und damit nicht ohne Weiteres von Symptomen des physiologischen Alterns und auch der Peri‑/Postmenopause abzugrenzen. Eine korrekte Diagnosestellung ist nicht zuletzt im Hinblick auf das in Peri‑/Postmenopause ohnehin erhöhte Osteoporose- und kardiovaskuläre Risiko relevant. Diskutiert werden (Differenzial‑)Diagnostik einschließlich zu berücksichtigender beeinflussender Faktoren sowie Therapie und Therapie-Monitoring auch in besonderen situativen Konstellationen.
Vorheriger Artikel Der Tryptophanstoffwechsel, seine Metaboliten und damit assoziierte Krankheiten
Nächster Artikel Update Osteoporose
Literatur
1.
Bjoro T et al (2000) Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 143:639–647PubMed
2.
Faughnan M et al (1995) Screening for thyroid disease at the menopausal clinic. Clin Invest Med 18:11–18PubMed
3.
Bojunga J (2015) Subklinische Schilddrüsenfunktionsstörungen in der Peri- und Postmenopause. J Gynäkol Endokrinol 25:6–11
4.
Hollowell JG et al (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499PubMed
5.
Mishra GD, Kuh D (2012) Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. BMJ 344:e402PubMedPubMedCentral
6.
Stuenkel CA et al (2015) Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100:3975–4011PubMed
7.
de los SET, Starich GH, Mazzaferri EL (1989) Sensitivity, specificity, and cost-effectiveness of the sensitive Thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 149:526
8.
Surks MI, Hollowell JG (2007) Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 92:4575–4582PubMed
9.
Kratzsch J et al (2005) New reference intervals for thyrotropin and thyroid hormones based on national academy of clinical biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem 51:1480–1486PubMed
10.
Chikunguwo S et al (2007) Influence of obesity and surgical weight loss on thyroid hormone levels. Surg Obes Relat Dis 3:631–635 (discussion 635–6)PubMed
11.
Bremner AP et al (2012) Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab 97:1554–1562PubMed
12.
Surks MI, Boucai L (2010) Age- and race-based serum thyrotropin reference limits. J Clin Endocrinol Metab 95:496–502PubMed
13.
Coene KLM (2015) et al. Subclinical hypothyroidism: a ‘laboratory-induced’ condition? Eur J Endocrinol 173:499–505PubMed
14.
Li D et al (2017) Association of biotin ingestion with performance of hormone and Nonhormone assays in healthy adults. JAMA 318:1150PubMedPubMedCentral
15.
Biscolla RPM, Chiamolera MI, Kanashiro I, Maciel RMB, Vieira JGH (2017) A single 10 mg oral dose of biotin interferes with thyroid function tests. Thyroid 27:1099–1100PubMed
16.
Gold EB et al (2013) Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol 178:70–83PubMedPubMedCentral
17.
Avis NE et al (2015) Duration of menopausal vasomotor symptoms over the menopause transition. Jama Intern Med 175:531PubMedPubMedCentral
18.
Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus Progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. J Am Med Assoc 288:321–333
19.
Gartlehner G et al (2017) Hormone therapy for the primary prevention of chronic conditions in postmenopausal women. JAMA 318:2234PubMed
20.
Techniker Krankenkasse (2018) Gesundheitsreport 2018 Fit oder fertig? Erwerbsbiografien in Deutschland
21.
Manson JE et al (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA 318:927PubMedPubMedCentral
22.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC (2000) The colorado thyroid disease prevalence study. Arch Intern Med 160:526PubMed
23.
Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 379:1142–1154PubMed
24.
Gussekloo J et al (2004) Thyroid status, disability and cognitive function, and survival in old age. JAMA 292:2591PubMed
25.
Simonsick EM et al (2009) Subclinical hypothyroidism and functional mobility in older adults. Arch Intern Med 169:2011PubMedPubMedCentral
26.
Oppo A, Franceschi E, Atzeni F, Taberlet A, Mariotti S (2011) Effects of hyperthyroidism, hypothyroidism, and thyroid autoimmunity on female sexual function. J Endocrinol Invest 34:449–453PubMed
27.
Luo H et al (2018) Subclinical hypothyroidism would not lead to female sexual dysfunction in Chinese women. BMC Womens Health 18:26PubMedPubMedCentral
28.
Hong H et al (2015) Subclinical hypothyroidism is not a risk factor for female sexual dysfunction in Korean middle-aged women. Thyroid 25:784–788PubMed
29.
Atis G et al (2010) Sexual dysfunction in women with clinical hypothyroidism and subclinical hypothyroidism. J Sex Med 7:2583–2590PubMed
30.
Biondi B (2007) Cardiovascular effects of mild hypothyroidism. Thyroid 17:625–630PubMed
31.
Hyland KA, Arnold AM, Lee JS, Cappola AR (2013) Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 98:533–540PubMed
32.
Somwaru LL, Rariy CM, Arnold AM, Cappola AR (2012) The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 97:1962–1969PubMedPubMedCentral
33.
Walsh JP et al (2010) Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab 95:1095–1104PubMed
34.
Stott DJ et al (2017) Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 376:2534–2544PubMed
35.
Meier C et al (2001) TSH-controlled l—Thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel thyroid study). J Clin Endocrinol Metab 86:4860–4866PubMed
36.
Feller M et al (2018) Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism. JAMA 320:1349PubMedPubMedCentral
37.
38.
Taylor PN et al (2014) Falling threshold for treatment of borderline elevated Thyrotropin levels—balancing benefits and risks. Jama Intern Med 174:32PubMed
39.
Mammen JS et al (2015) Thyroid hormone therapy and risk of Thyrotoxicosis in community-resident older adults: findings from the baltimore longitudinal study of aging. Thyroid 25:979–986PubMedPubMedCentral
40.
Peeters RP (2017) Subclinical hypothyroidism. N Engl J Med 376:2556–2565PubMed
41.
Carlé A, Faber J, Steffensen R, Laurberg P, Nygaard B (2017) Hypothyroid patients encoding combined MCT10 and DIO2 gene Polymorphisms May prefer L‑T3 + L‑T4 combination treatment—data using a blind, randomized, clinical study. Eur Thyroid J 6:143–151PubMedPubMedCentral
42.
Wiersinga WM (2017) Therapy of endocrine disease: T4 + T3 combination therapy: is there a true effect? Eur J Endocrinol 177:R287–R296PubMed
43.
Arafah BM (2001) Increased need for Thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 344:1743–1749PubMed
44.
Haugen BR (2009) Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 23:793–800PubMedPubMedCentral
45.
Mariotti S et al (1993) Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 77:1130–1134PubMed
46.
Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B (2008) Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 159:329–341PubMed
47.
Sawin CT et al (1994) Low serum Thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249–1252PubMed
48.
Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861–865PubMed
49.
Abe E et al (2003) TSH is a negative regulator of skeletal remodeling. Cell 115:151–162PubMed
50.
De Mingo Dominguez ML et al (2018) Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. Endocrine 62:166–173PubMed
51.
Leader A et al (2014) Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years. J Clin Endocrinol Metab 99:2665–2673PubMed
52.
Blum MR et al (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313:2055–2065PubMedPubMedCentral
53.
Tan ZS et al (2008) Thyroid function and the risk of alzheimer disease. The Framingham study. Arch Intern Med 168:1514PubMedPubMedCentral
54.
Díez JJ (2003) Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology 49:316–323PubMed
55.
Schouten BJ, Brownlie BEW, Frampton CM, Turner JG (2011) Subclinical thyrotoxicosis in an outpatient population—predictors of outcome. Clin Endocrinol (oxf) 74:257–261
56.
Das G et al (2012) Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (oxf) 77:146–151
57.
Bahn RS et al (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17:456–520PubMed
58.
Azizi F, Malboosbaf R (2017) Long-term Antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27:1223–1231PubMed
Metadaten
Titel
Schilddrüsenerkrankungen in der Peri- und Postmenopause
verfasst von
Dr. med. Antonia Mondorf
Gesine Meyer
Jörg Bojunga
Publikationsdatum
03.03.2021
Verlag
Springer Vienna
Erschienen in
Journal für Gynäkologische Endokrinologie/Schweiz / Ausgabe 1/2021
Print ISSN: 1995-6924
Elektronische ISSN: 2520-8500
DOI
https://doi.org/10.1007/s41975-021-00186-z

Weitere Artikel der Ausgabe 1/2021

Schweiz erneuert Osteoporose-Empfehlungen

Empfehlung zu Vitamin D im Rahmen der COVID-19-Pandemie

Editorial

  • Editorial

Endokrin inaktives Hypophysenadenom und sekundäre Nebennierenrindeninsuffizienz

  • Open Access
  • Der rätselhafte Fall

Der Tryptophanstoffwechsel, seine Metaboliten und damit assoziierte Krankheiten

  • Orthomolekulare Medizin

Neues aus der Schweizerischen Gesellschaft für Gynäkologische Endokrinologie und Menopause/SGEM

  • Neues aus der Schweizerischen Gesellschaft für Gynäkologische Endokrinologie und Menopause/SGEM